Drug Type Small molecule drug |
Synonyms 6-(4-((5-oxo-1,2,3,4,5,6-hexahydrobenzo[h][1,6]naphthyridin-8-yl)methyl)piperazin-1-yl)nicotinonitrile mono citrate, JPI 547, JPI-547 + [5] |
Target |
Action inhibitors |
Mechanism PARP inhibitors(Poly (ADP-Ribose) polymerase inhibitors), TNKS1 inhibitors(tankyrase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (South Korea) |
Molecular FormulaC23H24N6O |
InChIKeyGRPXLKXGJAGYSD-UHFFFAOYSA-N |
CAS Registry2055357-64-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Endometrial Cancer | Phase 2 | United States | 12 Sep 2024 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | South Korea | 31 Aug 2022 | |
Pancreatic Cancer | Phase 2 | South Korea | - | |
Pancreatic Cancer | Phase 2 | South Korea | - | |
Metastatic Pancreatic Cancer | Phase 1 | United States | 30 Mar 2022 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | United States | 30 Mar 2022 | |
Advanced Malignant Solid Neoplasm | Phase 1 | South Korea | 06 Dec 2017 | |
Advanced Malignant Solid Neoplasm | Phase 1 | South Korea | 06 Dec 2017 | |
Colorectal Cancer | Phase 1 | - | - | |
Colorectal Cancer | Phase 1 | - | - |
Phase 1 | 62 | (dose escalation) | jsrqfwacrp(jvxvhwymtg) = gujbbgstai ivcwdiyqrb (mpmhmgaxes ) View more | Positive | 20 May 2021 | ||
(dose escalation) | zxhacahdih(poaumymbtr) = ppfcjpvzds cuxamkqejw (jaantvkzig ) View more |